Indiplon Driving Study Could Add Marketing Momentum; Action Date Delayed
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer and Neurocrine Biosciences expect labeling for their insomnia drug indiplon could include language that the product does not appear to cause next-day sedation or driving impairment.